Hub proteins have central roles in regulating cellular processes. By targeting a single cellular hub, a viral oncogene may gain control over an entire module in the cellular interaction network that is potentially comprised of hundreds of proteins. The adenovirus E1A oncoprotein is a viral hub that interacts with many cellular hub proteins by short linear motifs/molecular recognition features (MoRFs). These interactions transform the architecture of the cellular protein interaction network and virtually reprogram the cell. To identify additional MoRFs within E1A, we screened portions of E1A for their ability to activate yeast pseudohyphal growth or differentiation. This identified a novel functional region within E1A conserved region 2 comprised of the sequence EVIDLT. This MoRF is necessary and sufficient to bind the N-terminal region of the SUMO conjugase UBC9, which also interacts with SUMO noncovalently and is involved in polySUMOylation. Our results suggest that E1A interferes with polySUMOylation, but not with monoSUMOylation. These data provide the first insight into the consequences of the interaction of E1A with UBC9, which was initially described in 1996. We further demonstrate that polySUMOylation regulates pseudohyphal growth and promyelocytic leukemia body reorganization by E1A. In conclusion, the interaction of the E1A oncogene with UBC9 mimics the normal binding between SUMO and UBC9 and represents a novel mechanism to modulate polySUMOylation.
Introduction
Cellular processes arise from an exquisitely complex series of molecular interactions. The correct execution of complex biological processes requires the precise interaction and regulation of thousands of proteins and is defined by complex molecular networks (Maslov and Sneppen, 2002; Rual et al., 2005; Stelzl et al., 2005; Gandhi et al., 2006) . Although most proteins interact with only one or two other proteins, a minority interact with tens, or even hundreds, of others to form network hubs. These hub proteins have key roles in regulating and orchestrating the activity of the proteins they interact with. They create functional modules within the cellular interactome and are frequently associated with cancer (Jeong et al., 2001; Fraser et al., 2002; Han et al., 2004) .
The central roles served by cellular hub proteins in regulating cellular functions make them ideal targets during a viral infection. By targeting a single cellular hub, a viral protein may gain control over an entire module, potentially comprised of hundreds of proteins. By targeting multiple cellular hubs, a virally encoded hub can transform the architecture of the cellular protein interaction network, reprogramming virtually all aspects of cell function and behavior, and this can lead to oncogenic transformation.
Human adenoviruses (HAd) were the first human viruses shown to induce tumors in animal models (Trentin et al., 1962) . Oncogenic transformation directly reflects the fundamental changes made to the cellular protein interaction network by virally encoded hub proteins in the infected cell. E1A is a key molecular hub in HAd (Frisch and Mymryk, 2002; Pelka et al., 2008) . Sequence comparisons of the E1A proteins of numerous HAds identified four regions of sequence similarity, designated CR1-4 (Avvakumov et al., 2002 (Avvakumov et al., , 2004 .
E1A is essential for a productive infection. It is the first viral gene expressed after infection and activates viral transcription (Mymryk and Smith, 1997; Berk, 2005) . It also reprograms host cell gene expression, forcing quiescent cells to enter and pass through the cell cycle and blocks or reverses differentiation (Bayley and Mymryk, 1994; Frisch and Mymryk, 2002) .
The multiple activities of E1A reflect its role as a viral molecular hub (Pelka et al., 2008) . E1A makes many independent connections to the cellular protein interaction network, and many of its targets are hub proteins themselves. Mechanistically, E1A alters or inhibits the normal function of these cellular proteins and may even establish new connections in the cellular network. Thus, E1A rewires the infected cell to create an environment conducive to viral replication (Ferrari et al., 2008) .
E1A consists of a collection of independent proteinbinding motifs, or molecular recognition features (MoRFs), which allow it to interact with a multitude of cellular targets. Identification of the protein interaction motifs within E1A and determination of the specific residues involved in intermolecular contacts have identified a number of MoRFs that are also present in cellular proteins. These include the PXDLS (where X is a variable) motif that binds the transcriptional corepressor CtBP (Chinnadurai, 2002) , the LXCXE motif that binds the cell cycle regulator pRb (Morris and Dyson, 2001) , the PXLXP motif that binds the BS69 corepressor (Ansieau and Leutz, 2002) and the FXD/EXXXL motif that binds CBP/p300 acetyltransferases (O'Connor et al., 1999) .
SUMO is a prominent member of the ubiquitin-like family, which is found in all eukaryotes (Geiss-Friedlander and Melchior, 2007) . Humans express four SUMO isoforms, whereas in yeast there is a single isoform (Smt3). All are processed to expose a C-terminal di-glycine motif required for their covalent attachment to lysine residues on target proteins. Conjugation requires an E1-activating enzyme and the E2 conjugase Ubc9. Ubc9 has a role in substrate recognition by binding a CKxE/D sequence often present in target proteins (Sampson et al., 2001) , and SUMO conjugation may involve E3 ligases (Schmidt and Muller, 2002) . SUMOylation has an important role in regulating transcription, protein trafficking, innate immunity and cell proliferation (Kerscher et al., 2006) . Substantial evidence suggests that SUMOylation has a role in oncogenesis. Indeed, many oncoproteins and tumor suppressors are regulated by SUMOylation (Dunnebier et al., 2009 ). In addition, UBC9 is overexpressed in melanomas, ovarian cancer and lung adenocarcinomas (Mo and Moschos, 2005) . UBC9 also regulates the response to DNA damage (Galanty et al., 2009; Morris et al., 2009; Prudden et al., 2009) . Interestingly, UBC9 can promote cell invasion, metastasis and sensitivity to anticancer agents independently from its critical role in SUMOylation (Mo et al., 2004; Zhu et al., 2009) , and has been suggested as a potential target for cancer therapy (Mo and Moschos, 2005) .
In this study, we identified a novel functional region within HAd5 E1A comprised of the sequence EVIDLT. This MoRF is necessary and sufficient to interact with the SUMO conjugase UBC9. E1A binds UBC9 by a surface previously shown to bind SUMO noncovalently and has a role in polySUMOylation (Capili and Lima, 2007; Knipscheer et al., 2007) . Our results suggest that this viral MoRF mimics an interaction normally present in uninfected cells and functions to inhibit polySUMOylation.
Results
Identification of a new region in E1A that activates yeast pseudohyphal growth We previously reported that the C-terminus/CR4 portion of HAd5 E1A activates pseudohyphal growth when expressed in yeast (Zhang et al., 2001) . To determine whether other portions of E1A could enhance pseudohyphal growth, we expressed the GAL4 DNA-binding domain fused to the N-terminus/CR1, CR2, CR3 and C-terminus/CR4 portions of E1A in S1278b strain of Saccharomyces cerevisiae. These experiments identified HAd5 E1A CR2 as a new peptide sequence that can activate yeast pseudohyphal growth (Figure 1 ). We also tested GAL4 DNA-binding domain fusions of E1A CR2 from six different serotypes (3, 4, 5, 9, 12 and 40, representing the six subgroups of HAd) for their ability to enhance pseudohyphal growth. Only the CR2 regions of HAd5 E1A enhanced pseudohyphal growth (Supplementary Figure S1A ).
The FLO11 promoter driving the expression of the b-galactosidase reporter gene (LacZ) can be used as a quantitative measure of pseudohyphal growth (Rupp et al., 1999) . Of the six different serotypes tested, only HAd5 E1A CR2 could activate FLO11-dependent transcription (Supplementary Figure S1B) , paralleling their effects on pseudohyphal growth (Supplementary Figure S1A ).
HAd5 E1A CR2 interacts with the SUMO conjugase UBC9 Although UBC9 was originally identified as a target of E1A CR2, the consequences of this interaction remain undetermined (Hateboer et al., 1996) . We tested E1A's ability to bind UBC9 using the yeast two-hybrid system and through a mammalian coimmunoprecipitation assay. The human embryonic kidney cell line HEK293, which expresses HAd5 E1A, was stably transfected with Myc epitope-tagged mammalian UBC9 to construct UMBRA cells. Immunoprecipitation of UBC9 from UMBRA cell extract shows that the two major isoforms of E1A were coimmunoprecipitated (Figure 2a) . This was the first time an interaction between E1A and UBC9 was detected in the context of a mammalian cell.
The interaction between E1A and UBC9 was initially detected using the yeast two-hybrid system (Hateboer et al., 1996) . HAd5 E1A CR2 interacts with both mouse and yeast UBC9 in this assay (Figure 2b ), but not the yeast Ubc5 or Rad6 ubiquitin conjugases (Figure 2c) . The results indicate that E1A does indeed interact with UBC9 in vivo, and that this interaction seems specific to the SUMO conjugation pathway.
E1A interacts with UBC9 and activates pseudohyphal growth through residues 118-123 To determine the portion of E1A CR2 that was required for activating the FLO11 promoter, we tested CR2 deletion mutants for their ability to activate FLO11 transcription (Figures 3a and b) . Activation required residues 112-123 of E1A. Similarly, the same residues were required for interaction with mammalian or yeast UBC9 in a yeast two-hybrid assay (Figure 3c ). In addition, the D112-117 E1A mutant was still able to bind UBC9 (Figure 3c ). This suggested that interaction requires residues 118-123 of E1A, corresponding to the peptide EVIDLT.
The peptide EVIDLT was sufficient to activate pseudohyphal growth and activate the FLO11 promoter (Figures 4a and b) . Mutating threonine to histidine in the EVIDLT peptide (residue 123 in full-length E1A) abrogated both activities. Furthermore, EVIDLT was sufficient to interact with mouse and yeast UBC9 in a yeast two-hybrid system, and the T123H mutation abolished this activity (Figure 4c ). This suggests that activation of pseudohyphal growth by E1A CR2 results from its ability to interact with the SUMO conjugase UBC9.
EVIDLT is a UBC9-binding MoRF and not a SUMO-interacting motif The peptide sequences (V/I)X(V/I)(V/I) or (V/I)(V/I) X(V/I/L) can confer interaction with SUMO and are referred to as SUMO-interacting motifs (Song et al., 2004 (Song et al., , 2005 . The EVIDLT sequence we identified in E1A contains a consensus SUMO-interacting motif of the type VIXL. As SUMO and UBC9 physically interact, the binding between UBC9 and E1A could be indirectly bridged by SUMO. To assess this, we tested UBC9 and SUMO-1 mutants that will not covalently interact with each other for their ability to interact with E1A in a yeast two-hybrid system.
The catalytic cysteine (C93) in UBC9 makes a thioester bond with G97 in SUMO during the process of SUMOylation. Thus, a UBC9 C93S mutant or a mutant in SUMO-1 that removes G97 loses the ability to covalently interact with each other. A UBC9 C93S mutant and two SUMO-1 mutants (G97A and SUMO 1-95, which lacks the C-terminus) were tested for interaction with each other and E1A. As predicted, UBC9 C93S was deficient for interaction with wild-type SUMO-1 (Figure 5a ). Furthermore, the SUMO-1 G97A and 1-95 mutants were deficient for interaction with wild-type UBC9 (Figure 5b ). E1A weakly interacted with SUMO-1, but this is abrogated by elimination of the di-glycine motif, suggesting that association is indirectly bridged by endogenous yeast Ubc9. However, E1A retains binding to the UBC9 C93S mutant ( Figure 5c ). This shows conclusively that E1A interacts with UBC9 independently of SUMO-1.
Mutational analysis of the EVIDLT MoRF
To determine the residues in the EVIDLT MoRF that were important for UBC9 interaction, we mutated each residue in the motif to alanine and tested the ability of these mutants to bind UBC9. The only residue that tolerated a mutation to alanine was E118 (Supplementary Figure S2B ). In addition, four other more conservative mutations, D121E, D121N, T123Y and T123S, 
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Figure 1 HAd5 E1A CR2 and CR4 enhance pseudohyphal differentiation when expressed as Gal4 DNA-binding domain fusions in S1278b strain yeast. The indicated portions of E1A were expressed as Gal4 DNA-binding domain fusions in S1278b strain yeast and streaked onto SLAD plates. The colonies were visualized using light microscopy at Â 400 magnification and photographed with a Sony Power HAD 3CCD color video camera (Sony of Canada Ltd., Toronto, ON, Canada) using Northern Eclipse Imaging Analysis Software (Empix Imaging Inc, Mississauga, ON, Canada).
were also assessed (Supplementary Figure S2C) . None of these bound UBC9. Thus, each residue within the UBC9-interacting motif of E1A is critical, with the apparent exception of E118.
The interaction of E1A with UBC9 does not perturb global SUMOylation and is not necessary for oncogenic transformation To assess the functional consequences of the interaction of E1A with UBC9, several different test systems were used.
To determine whether E1A interferes with SUMO conjugation, we performed in vitro monoSUMOylation assays. Neither GST-E1A nor GST-CR2 affected monoSUMOylation of HDAC4 (data not shown) or E2-25K (Supplementary Figure S3) . Furthermore, western blots of A549 and U2OS cells transfected with HA-tagged SUMO-1, SUMO-2 or SUMO-3 with and without E1A showed no obvious differences (Supplementary Figure S4 ). Thus, E1A does not affect global in vivo SUMOylation.
The UBC9-binding region of E1A resides within CR2, which is required for oncogenic transformation. To determine whether transformation was dependent on interaction with UBC9, we transfected either wild-type or p53
À/À primary mouse embryonic fibroblasts (MEFs) with E1A, E1A dl1107 or the E1A T123H mutant, which does not bind UBC9, and scored the number of foci that appeared. As expected (Lowe et al., 1994) , E1A caused the formation of multiple foci in p53 À/À MEFs and this was abrogated by the dl1107 mutant, which does not bind pRb (Supplementary Figure S5) . The T123H E1A mutant transformed p53 À/À MEFs at a frequency equivalent to wild-type E1A, indicating that binding with UBC9 is not required to transform MEFs.
E1A's effects on promyelocytic leukemia (PML) bodies PML nuclear bodies are supramolecular complexes found in the nucleus of mammalian cells (Dellaire and Bazett-Jones, 2004) . They have been implicated in almost every nuclear cellular process, including transcription, DNA repair, stress response, cell proliferation, apoptosis and viral defense (Bernardi and Pandolfi, 2007) . PML bodies contain PML protein, which is SUMOylated, and SUMOylation has a role in accumulation of various proteins in PML bodies (Dellaire and Bazett-Jones, 2004) . Cell nuclei typically contain 10-30 PML bodies (Dellaire and Bazett-Jones, 2004) . E1A redistributes and reorganizes PML bodies in the nucleus (Eskiw et al., 2003) . To determine whether E1A's ability to affect PML body formation was dependent on interaction with UBC9, we expressed E1A or E1A T123H in U2OS cells stably expressing green fluorescent protein-tagged PML-IV. As reported (Eskiw et al., 2003) , wild-type E1A caused a reorganization of PML bodies, causing them to seem larger in size and fewer in number (Figure 6a ). The E1A T123H mutant exhibited a reduced ability to increase the size of PML bodies (Figures 6a and b) . The E1A T123H mutant was also localized differently, such that it was present in both the cytoplasm and the nucleus, whereas wild-type E1A was E1A interaction with UBC9 AF Yousef et al localized to the nucleus only (Figures 6a and c) . There was no difference in PML expression between cells expressing E1A or the E1A T123H mutant (Supplementary Figure S6 ). Furthermore, neither wild type nor T123H E1A obviously affected the localization of UBC9 in U2OS cells, which is found equally in the cytoplasm and nucleus (data not shown). These results show that interaction of E1A with UBC9 influences E1A's localization and is at least partially responsible for the effects of E1A on PML body formation.
Mapping the E1A-binding surface on UBC9
We mapped the surface on UBC9 contacted by E1A. Deletion of 10 or more amino acids from the N-terminus of UBC9 (D10, D25 and D50) abrogated interaction with E1A (Supplementary Figure S7) , whereas deletion of the N-terminal five amino acids had no effect. On the basis of the structure of UBC9, the N-terminal deletions we tested removed helix 1, with the exception of the D5 mutant. This suggests that E1A binds helix 1 of UBC9. In contrast, the C-terminal 27 amino acids of UBC9 (1-132) were not required to bind E1A (Supplementary Figure  S7) . The interaction was also compromised with larger C-terminal deletions, likely due to improper folding of the globular UBC9 protein (Supplementary Figure S7) .
The N-terminal helix of UBC9 shows a weak noncovalent interaction with the C-terminus of SUMO (Capili and Lima, 2007; Knipscheer et al., 2007) . As this helix is also important for binding E1A, we compared the sequence of E1A with the C-terminus of SUMO. Interestingly, the peptide sequence 86À DVIEVY À91 in SUMO-1, which interacts with helix 1 of UBC9, is similar to the 118À EVIDLT À123 sequence that we identified in E1A (Supplementary Figure S8) . We tested UBC9 point mutants that affect the surface that binds SUMO noncovalently for their ability to bind E1A. The R13E, R17E and H20D UBC9 mutants that do not bind SUMO (Capili and Lima, 2007; Knipscheer et al., 2007) also failed to interact with E1A (Figure 7a) . Furthermore, the G23R and V25R mutants that retained noncovalent SUMO binding (Knipscheer et al., 2007) still bound E1A (Figure 7a ). In contrast, UBC9 F22A, which retains noncovalent interaction with SUMO (Knipscheer et al., 2007) , failed to interact with E1A ( Figure 7a ). These data indicated that E1A and SUMO were making contact with a similar, but not identical, surface on UBC9.
In addition, three more UBC9 mutants (K18E, D19K and M36S) that affect this surface of UBC9 were tested for their ability to interact with E1A. All three of these mutants retained binding with E1A (Figure 7a ). UBC9 E1A interaction with UBC9 AF Yousef et al itself undergoes SUMOylation at K14 (Knipscheer et al., 2008) . A UBC9 K14R mutant was still able to bind E1A, indicating that SUMOylation of UBC9 was not required for association with E1A (Figure 7a ). The result of this mutational analysis was the identification of a well-defined surface on UBC9, which is required for binding E1A (Figure 7b ).
In the crystal structure of the noncovalent association of UBC9 with SUMO-1 (Capili and Lima, 2007) (accession number 2pe6), R17 and H20 in UBC9 make ionic contacts with D86 and V87 in SUMO-1, respectively. D86 and V87 correspond to E118 and V119 in the E1A peptide, which explains why mutation of R17 and H20 in UBC9 also affected E1A binding. A model of the interaction of E1A with UBC9 was constructed by replacement of the 86À DVIEVY À91 sequence from SUMO-1 in this crystal structure with the similar E1A sequence EVIDLT, followed by refinement with subsequent rounds of energy minimization. In this model, E1A T123 is predicted to make a hydrophobic interaction with UBC9 F22, which is lost by substitution with serine or alanine. We hypothesized that a T123V mutation would retain binding between E1A and UBC9 through the hydrophobic interaction with UBC9 F22. As predicted, the EVIDLV peptide retained a measureable ability to interact with UBC9, which was not observed with the EVIDLS peptide or the other mutant peptides tested (Figure 7c versus Supplementary Figure S2 ).
E1A suppresses a growth defect in yeast lacking a SUMO protease
In yeast, the Ulp2 SUMO/Smt3 protease counteracts polySUMOylation (Schwienhorst et al., 2000; Bylebyl et al., 2003) . Ulp2D yeasts are unable to grow at 37 1C, likely because of a toxic accumulation of polySUMOylated proteins (Uzunova et al., 2007) . We reasoned that the interaction of E1A with the N-terminus of UBC9 would block the noncovalent interaction of SUMO necessary for polySUMOylation. This would impair SUMO chain formation and the accumulation of toxic polySUMOylated proteins. Expression of E1A CR2 or the EVIDLT sequence in an Ulp2D yeast strain restored growth at 37 1C almost as efficiently as the reintroduction of Ulp2 (Figure 8a) . However, the EVIDLH sequence, which does not bind UBC9, did not restore growth. These results suggest that the interaction of E1A with UBC9 suppresses polySUMOylation.
PolySUMOylation regulates yeast pseudohyphal growth
Our data suggest that suppression of polySUMOylation is responsible for the increase in pseudohyphal growth observed with E1A CR2, providing the first link between polySUMOylation and pseudohyphal growth. We tested this directly by constructing diploid yeast expressing the dominant-negative Smt3 K11/15/19R mutant. This mutant cannot form chains, as it lacks the target lysines necessary for SUMO/Smt3 branching (Uzunova et al., 2007) . Incorporation of this mutant protein into existing SUMO/Smt3 chains blocks chain extension that should effectively reproduce the consequences of expressing E1A CR2. As predicted, expression of the dominant-negative Smt3 mutant enhanced pseudohyphal growth in a manner similar to that of E1A CR2, and, in combination with CR2, resulted in an even greater effect (Figure 8b) . We also constructed a diploid yeast strain heterozygous for the gene encoding the Ulp2 Smt3/SUMO protease. This strain would be expected to accumulate polySUMOylated proteins (Uzunova et al., 2007) . In this background, the ability of E1A CR2 to stimulate pseudohyphal growth was compromised (Figure 8b ). These results suggest that the suppression of polySUMOylation induced by E1A CR2 is counterbalanced by E1A interaction with UBC9 AF Yousef et al the accumulation of polySUMOylated proteins in the Ulp2D/Ulp2 strain. Collectively, these data strongly support a novel role for polySUMOylation in the control of pseudohyphal growth.
Discussion
E1A is a viral hub oncoprotein that interacts with many cellular proteins by short linear MoRFs. By screening portions of E1A for their ability to activate yeast pseudohyphal growth, we identified a novel functional region comprised of the sequence EVIDLT (Figures 1, 4 and 8). This MoRF is necessary and sufficient to interact with the SUMO conjugase UBC9 (Figures 2-4) . EVIDLT or similar sequences are present in cellular proteins involved in SUMOylation, raising the exciting possibility that this MoRF is also present in cellular proteins (Supplementary Figure S8) . SUMOylation regulates multiple cellular processes, including transcription control, intracellular protein trafficking, apoptosis, innate immunity, differentiation, DNA damage response, as well as cell cycle control (Kerscher et al., 2006) . This makes the SUMO/UBC9 hub in the cellular interaction network a prime target for a viral oncoprotein similar to E1A. To identify the molecular determinants of the UBC9-interacting MoRF in E1A, we mutated each residue in the EVIDLT motif. Each amino acid, with the exception of E118, was necessary for binding UBC9 (Supplementary Figure S2) . However, E118 is critical for binding in the context of E1A (Figure 3c) . Binding of the E118A peptide to UBC9 likely resulted from an adjacent glutamic acid from the Gal4 DNA-binding domain fusion, suggesting that there is flexibility in the location of this negative charge. Although the EVIDLT peptide bound yeast and mouse UBC9 equivalently, CR2 bound to mouse better than to yeast UBC9. This suggests that E1A CR2 may make additional contacts with mouse UBC9.
We determined that E1A binds the N-terminus of UBC9 (Supplementary Figure S7) . This surface is distinct from that required for the interaction of UBC9 with the Sae2 E1-activating enzyme and the catalytic site (Wang et al., 2007) , or interaction with the CKxE/D motif in a target substrate (Lin et al., 2002) . Thus, E1A should not affect the ability of UBC9 to accept activated SUMO from Sae2 or recognize and modify a target substrate, which agrees with our observation that E1A does not affect in vitro monoSUMOylation (Supplementary Figure S3) . The only other proteins known to interact with the N-terminus of UBC9 are the Rad60 family members. These proteins bind UBC9 by large integral SUMO-like domains, which adopt a b-grasp fold similar to SUMO; these interactions promote cellular responses to genotoxic stress (Prudden et al., 2009; Sekiyama et al., 2009) . Our discovery that the short linear MoRF EVIDLT in E1A recapitulates this interaction is unprecedented.
The E1A-binding surface on UBC9 (Figures 7a and b ) is similar to that used for binding SUMO-1 noncovalently (Knipscheer et al., 2007) and the E1A MoRF is 
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AF Yousef et al similar to the SUMO-1 sequence that contacts that portion of UBC9. SUMO-1 binding to the N-terminus of UBC9 is required for the formation of SUMO chains in vitro (Knipscheer et al., 2007) , suggesting that E1A suppresses polySUMOylation by competing for interaction with this surface. Evidence that E1A with UBC9 reduces polySUMOylation was provided by our observation that the EVIDLT MoRF was necessary and sufficient to suppress the growth defects that arise in an Ulp2-deficient yeast strain because of the accumulation of toxic polySUMOylated products (Figure 8a ). Further support for the role of E1A in suppressing polySUMOylation is provided by our observation that expression of a dominant-negative SUMO/Smt3 protein that blocks SUMO chain formation induces pseudohyphal growth in a manner similar to that of E1A CR2 (Figure 8b ).
Little is known about the function of polySUMOylation, but it is induced by heat, oxidative or osmotic stress (Saitoh and Hinchey, 2000) . In addition, SUMO-targeted ubiquitin ligases recognize SUMOylated proteins and polyubiquitylate them, targeting them for degradation (Prudden et al., 2007; Sun et al., 2007; Xie et al., 2007; Mullen and Brill, 2008; Weisshaar et al., 2008) . Interestingly, PML is the only protein in mammalian cells identified so far that is targeted by the RNF4 SUMOtargeted ubiquitin ligases (Lallemand-Breitenbach et al., 2008; Tatham et al., 2008) , and E1A had an observable effect on PML localization that was specifically dependent on binding UBC9 (Figure 6 ).
SUMOylation of UBC9 at K14 affects substrate specificity (Knipscheer et al., 2008) . Although binding of E1A to UBC9 is independent of K14 (Figure 7a ), this residue is close to the E1A-binding surface (Figure 7b ). Thus, E1A could interfere with SUMOylation of UBC9, potentially influencing substrate specificity in addition to polySUMOylation.
In conclusion, this work represents the first advance in understanding the molecular basis and consequences of the interaction of E1A with UBC9 over the 14 years since UBC9 was first cloned, on the basis of its association with E1A. It is important to note that we have identified a new MoRF in E1A comprised of the sequence EVIDLT that interacts with the N-terminus of UBC9 in a manner similar to SUMO. Mimicry of this interaction by a viral oncogene such as E1A is highly suggestive of the fact that this module in the cellular interaction network is vitally important. Our data also set the stage for determining the specific biological consequences of a reduction in polySUMOylation and suggest that E1A could be a useful reagent in these studies, as it has been for other cellular proteins, such as pRb, p300/CBP and CtBP (Pelka et al., 2008) . It is intriguing that this UBC9-binding MoRF that we identified in E1A seems to be present in cellular proteins, suggesting that they may similarly influence polySUMOylation.
Materials and methods
Plasmids, yeast strains, cell lines and media Plasmid and their sources are listed in Supplementary Table  S1 . Yeast strains and their sources are listed in Supplementary  Table S2 . Yeast strains used for pseudohyphal growth assays are derived from the yeast strain S1278b (Zhang et al., 2001 ). Yeast two-hybrid assays were carried out in the strain L40. 
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Growth assays for pseudohyphal differentiation were performed as described previously (Zhang et al., 2001) . UMBRA cells were constructed by transfecting human embryonic kidney 293 cells with pCAN-Myc-UBC9 and selecting them with 500 mg/ml neomycin. The U2OS green fluorescent protein-PML IV cells were obtained from Dr Jerry Taylor (Medical College of Wisconsin, Milwaukee, WI, USA).
Mammalian cells lines were grown in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, streptomycin or penicillin, and glutamine. Transfections were carried out using SuperFect (Qiagen Inc., Mississauga, ON, Canada).
b-galactosidase assays b-galactosidase assays were performed as previously described . All assays were carried out in triplicate and are presented as the average activity with the standard deviation.
Coimmunoprecipitation assays
For immunoprecipitation of Myc-UBC9, 293 HEK or UMBRA cells were lysed in NP-40 lysis buffer (0.5% NP-40, 50 mM Tris (pH 7.8), 150 mM NaCl) and supplemented with protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA). A volume of 1.5 mg of the cell lysate was used for immunoprecipitation with the 9E10 a-Myc antibody. E1A was detected using the M73 antibody.
Global mammalian SUMOylation assays
Cells were transfected with Myc-UBC9 and with either HA-SUMO1, HA-SUMO-2 or HA-SUMO3 and with either allele, which encodes an Smt3 protein that is deficient in forming chains, undergoes enhanced pseudohyphal growth. E1A's ability to induce pseudohyphal differentiation is inhibited in an Ulp2 disruption strain. The C-terminus/CR4 portion of E1A enhances pseudohyphal growth by a different mechanism and is unaffected in these different strains.
pCDNA3, pCDNA3-13S E1A or pCDNA3-13S E1A T123H. Cells were lysed in radioimmunoprecipitation buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% sodium dodecyl sulfate) supplemented with protease inhibitor cocktail (Invitrogen Corporation, Carlsbad, CA, USA) and 25 mM N-ethylmaleimide. A volume of 40 mg of cell lysate was resolved on 5-20% gradient Tris-glycine polyacrylamide gel electrophoresis gels (Invitrogen Corporation). SUMO was detected using the 3F10 a-HA antibody (Roche Canada, Laval, QC, Canada).
Mouse embryonic fibroblast foci-forming assays Primary wild-type or p53 À/À MEFs were transfected with either pCDNA3 or a pCDNA3 vector expressing wild-type E1A, E1A dl1107 or E1A T123H. Cells were split into two 10 cm plates after 4 days and allowed to grow for 4 weeks. Cells were fixed using 4% paraformaldehyde, stained with 5% giemsa and foci enumerated.
Immunofluorescence microscopy A total of 30 000 cells per well were seeded and cultured in Lab-Tek II-chamber slides (Nalge Nunc International, Rochester, NY, USA) and transfected. Cells were fixed in 4% paraformaldehyde and permeabilized in 0.1% Triton X-100. Primary antibody was diluted to a ratio of 1:400 in blocking buffer (PBST, 1% goat serum, 1% bovine serum albumin). Secondary AlexaFluor-conjugated antibodies (Invitrogen Corporation) were diluted to a ratio of 1:400 in blocking buffer. A volume of 300 nM 4 0 ,6-diamidino-2-phenylindole (Molecular Probes, Invitrogen Corporation) in phosphatebuffered saline was used to stain nuclei. Cells were mounted using DABCO and Geltol (Sigma-Aldrich and ThermoElectron, Pittsburg, PA, USA, respectively) and visualized using an Olympus FluoView FV1000 laser confocal microscope (Markham, ON, Canada).
In vitro SUMOylation assays In vitro SUMOylation assays were performed using the SUMO Conjugation Kit (K-710; Boston Biochemicals, Cambridge MA, USA) according to the manufacturer's instructions.
